NURS 5334 ADVANCE PHARM MODULE 6 PART 2
FINAL EXAM QUESTIONS AND ANSWERS LATEST
UPDATED 2025 (GRADED)
ovaryMsequenceMthatMoccurs:M-McorrectManswer-
(1)MseveralMovarianMfolliclesMripen;M(2)MoneMofMtheMripeMfolliclesMruptures,McausingMovulation;M(3)MtheMru
pturedMfollicleMevolvesMintoMaMcorpusMluteum;MandM(4)MifMfertilizationMdoesMnotMoccur,MtheMcorpusMluteu
mMatrophies.
UterusMsequenceMthatMoccursM-McorrectManswer-
(1)MwhileMovarianMfolliclesMripen,MtheMendometriumMpreparesMforMnidationM(implantationMofMaMfertilizedM
ovum)MbyMincreasingMinMthicknessMandMvascularity;M(2)MafterMovulation,MtheMuterusMcontinuesMitsMprepara
tionMbyMincreasingMsecretoryMactivity;MandM(3)MifMimplantationMfailsMtoMoccur,MtheMthickenedMendometriu
mMbreaksMdown,McausingMmenstruation,MandMtheMcycleMbeginsMagain
EstrogensM-McorrectManswer-
supportMtheMdevelopmentMandMmaintenanceMofMtheMfemaleMreproductiveMtractMandMsecondaryMsexMcharact
eristics.M
TheseMhormonesMareMrequiredMforMtheMgrowthMandMmaturationMofMtheMuterus,Mvagina,MfallopianMtubes,Man
dMbreasts.MInMaddition,MestrogensMdirectMpigmentationMofMtheMnipplesMandMgenitalia.
EstrogensMonMfollicularMphaseMofMmenstrualMcycleM-McorrectManswer-
haveMaMprofoundMinfluenceMonMphysiologicMprocessesMrelatedMtoMreproduction.M
MpromoteM(1)MductalMgrowthMinMtheMbreast,M(2)MthickeningMandMcornificationMofMtheMvaginalMepithelium,M
(3)MproliferationMofMtheMuterineMepithelium,MandM(4)McopiousMsecretionMofMthickenedMmucusMfromMendoc
ervicalMglands
increaseMvaginalMacidity
declineMinMlevelsMcanMbringMonMmenstruation
EstrogenMTherapeuticMusesM-McorrectManswer-
includeMmenopausalMhormoneMtherapyM(HT);MfemaleMhypgonadism;MacneM(oralMcontraceptives);McancerM
palliation;MgenderMaffirmationMtherapyMforMtransgenderMwomen.MAEsMincludeMendometrialMhyperplasia,Me
ndometrialMcancerM;breastMcancer;MCVMthromboembolicMevents/MgallbladderMdisease,Mjaundice,Mheadache
;Mnausea,MfluidMretention,MandMchloasma.
,EstrogenMcontraindicationsM-McorrectManswer-
shouldMnotMbeMtakenMbyMpatientsMwithMaMhistoryMofMdeepMveinMthrombosisM(DVT),MpulmonaryMembolus,M
orMconditionsMsuchMasMstrokeMorMmyocardialMinfarctionM(MI)MthatMoccurredMsecondaryMtoMaMthromboemb
olicMevent.TheyMshouldMnotMbeMprescribedMtoMwomenMwhoMareMpregnantMorMwhoMhaveMvaginalMbleedingM
withoutMaMknownMcause.MPatientsMwithMaMhistoryMofMliverMdisease,Mestrogen-
dependentMtumors,MorMbreastMcancerM(exceptMwhenMindicatedMforMmanagement)MalsoMshouldMnotMtakeMest
rogens.
TrandermalMestradiolM-McorrectManswer-
emulsionM(Estrasorb);MsprayM(Evamist);MGelsM(EstroGel,MElestrin,MDivigel);MPatchesM(Alora,MClimara,ME
straderm,Mmonostar,Mvivelle-dot,MandMOesclim
emulsionM(Estrasorb)M-McorrectManswer-
isMappliedMonceMdailyMtoMtheMtopMofMbothMthighsMandMtheMbackMofMbothMcalves
instructMtheMpatientMtoMapplyMinMtheMmorning
evamistM-McorrectManswer-TheMsprayMisMappliedMonceMdailyMtoMtheMforearm.
instructMpatientMtoMapplyM1,M2,MorM3MspraysMonceMdailyMandMthenMletMdryMforMandMleastM2MminMbeforeMdre
ssingMandM30MminMbeforeMwashing
(Divigel)M-McorrectManswer-
TheMgelMisMappliedMonceMdailyMtoMoneMarm,MfromMtheMshoulderMtoMtheMwristMorMtoMtheMthighM
applyMonceMafterMshowering
Alora,MClimara,MEstraderm,Mmonostar,Mvivelle-dot,MandMOesclimM-McorrectManswer-
TheMpatchesMareMappliedMtoMtheMskinMofMtheMtrunkM(butMnotMtheMbreasts).MRatesMofMestrogenMabsorptionM
withMtransdermalMformulationsMrangeMfromM14MtoM60Mµg/24Mhours,MdependingMonMtheMproductMused.
ifMtheMpatchMfallsMoffMreapplyMtheMsameMorMplaceMaMnewMpatchM
rotateMapplicationMsites
transdermalMformulationsMhaveMfourMadvantages:M-McorrectManswer-
TheMtotalMdoseMofMestrogenMisMgreatlyMreducedM(liverMisMbypassed);MlessMnauseaMandMvomiting;MbloodMle
velsMofMestrogenMfluctuateMless;MthereMisMaMlowerMriskMforMDVT,MPE,MandMstroke
, intravaginalMinsertsM(Imvexxy,MVagifem,MYuvafem)M-McorrectManswer-
usedMforMlocalMeffects,MprimaryMtreatmentMofMvulvalMandMvaginalMatrophyMassociatedMfromMwithMmenopa
use.M
consistMofMoneMinsertMforM2Mweeks.
IntravaginalMcreamsM(EstraceMVaginal,MPremarinMVaginalM-McorrectManswer-
instructMtheMpatientMtoMappleMestrogenMcreamMhighMintoMtheMvagina,MusuallyMatMbedtime
vaginalMringsM-McorrectManswer-
(Estring)MareMusedMonlyMforMlocalMeffects,MprimarilyMtreatmentMofMvulvalMandMvaginalMatrophyMassociated
MwithMmenopause.M
TheM(Femring)MisMusedMforMsystemicMeffectsM(e.g.,McontrolMofMhotMflashesMandMnightMsweats)MasMwellMasM
localMeffectsM(e.g.,MtreatmentMofMvulvalMandMvaginalMatrophy
insertMasMdeepMasMpossibleMandMleaveMinMplaceMforM3Mmonth
ParenteralMestrogenM-McorrectManswer-
formulatedMforMintravenousM(IV)MandMintramuscularM(IM)Madministration,MuseMofMtheseMroutesMisMrare.MI
VMadministrationMisMgenerallyMlimitedMtoMacute,MemergencyMcontrolMofMheavyMuterineMbleeding.
PhytoestrogensM-McorrectManswer-areMplant-
basedMcompoundsMthatMhaveMweakMestrogenicMactivity.MthreeMtypes:Misoflavones,Mlignins,MandMcoumestan
s.M
MmostMcommonlyMusedMandMstudiedMareMtheMisoflavonesMwhichMareMderivedMfromMplantsMsuchMasMsoyMbe
ansMandMredMclover.M
MareMnotMasMpotentMasMestradiol,MbutMtheyMcarryMsomeMofMtheMsameMrisks.heMAmericanMAssociationMofMCl
inicalMEndocrinologistsMsuggestMthatMwomenMpreferringMtoMuseMshouldMbeMencouragedMtoMobtainMtheseMin
gredientsMfromMwholeMfoodMsourcesMtoMavoidMoverdosage.
PhytoestrogensMtherapeuticMusesM-McorrectManswer-
areMcommonlyMusedMbyMwomenMasMaM"natural"MwayMtoMmanageMsymptomsMassociatedMwithMmenopause.M
ThereMisMstrongManecdotalMsupportMforMtherapy;Mhowever,MfindingsMfromMrandomizedMcontrolledMtrialsMar
eMinconsistent.MTheMareMnotMreallyMrecommendedMorMdiscouraged.
MWomenMshouldMnotMuseMifMtheyMhaveMaMhistoryMofMthromboembolicMeventsMorMaMpersonalMorMfamilyMhis
toryMofMbreast,Muterine,MorMovarianMcancer.MT
